DBV Technologies

DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy
DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy
Pharmaceutical Business Review
Viaskin Peanut
DBV Technologies
FDA
peanut allergy
Flag link:
DBV Technologies Resubmits BLA for Peanut Allergy Treatment
DBV Technologies Resubmits BLA for Peanut Allergy Treatment
BioSpace
DBV Technologies
FDA
peanut allergy
Viaskin Peanut
Flag link:
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
Endpoints
peanut allergy
Aimmune Therapeutics
DBV Technologies
ICER
AR101
Viaskin Peanut
Flag link:
DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead
DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead
Xconomy
DBV Technologies
Aimmune
peanut allergy
AR-101
Viaskin Peanut
Flag link:
DBV Technologies pulls peanut allergy treatment from FDA review
DBV Technologies pulls peanut allergy treatment from FDA review
Stat
DBV Technologies
peanut allergy
FDA
Viaskin Peanut
Flag link:
DBV climbs as messy milk allergy data open door to phase 3
DBV climbs as messy milk allergy data open door to phase 3
Fierce Biotech
DBV Technologies
food allergies
milk allergy
Viaskin Milk
Flag link:
DBV climbs as peanut allergy safety data come in clean
DBV climbs as peanut allergy safety data come in clean
Fierce Biotech
peanut allergy
DBV Technologies
Viaskin Peanut
Flag link:
A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway
A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway
Stat
vaccines
food allergies
peanut allergy
DBV Technologies
Viaskin Peanut
Flag link:
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Flag link:
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
EP Vantage
R&D
Kite Pharma
Incyte
Portola Pharmaceuticals
DBV Technologies
Axovant
AveXis
Flag link:
Europe Biotechs Aim to Catch Americans as Investors Embrace IPOs
Europe Biotechs Aim to Catch Americans as Investors Embrace IPOs
Bloomberg
biotech
IPOs
Europe
DBV Technologies
GW Pharma
Flag link:
DBV files to raise $245M to fuel race for peanut allergy market
DBV files to raise $245M to fuel race for peanut allergy market
Fierce Biotech
DBV Technologies
peanut allergy
Viaskin
Viaskin Peanut
Flag link:
DBV makes a beeline for Phase III as peanut allergy race hots up
DBV makes a beeline for Phase III as peanut allergy race hots up
Fierce Biotech
DBV Technologies
vaccines
food allergies
peanut allergy
Viaskin Peanut
Flag link:
Peanut Allergy Patch Quest Has French Company Spurning Suitors
Peanut Allergy Patch Quest Has French Company Spurning Suitors
Bloomberg
peanut allergy
DBV Technologies
Viaskin
Flag link: